Document:

EX-10.21

 Exhibit 10.21 

FIFTH AMENDMENT 
 TO
LOAN AND SECURITY AGREEMENT 
 This Fifth Amendment to Loan and Security Agreement (the “Amendment”) is made
and entered into as of December 1, 2016 by and between PACIFIC WESTERN BANK, a California state chartered bank (“Bank”), and ALDEYRA THERAPEUTICS, INC. (“Borrower”). 

RECITALS 
 Borrower
and Bank are parties to that certain Loan and Security Agreement dated as of April 12, 2012 (as amended from time to time, the “Agreement”). The parties desire to amend the Agreement in accordance with the terms of this
Amendment. 
 NOW, THEREFORE, the parties agree as follows: 
  

	1)	The following defined terms in Exhibit A to the Agreement are hereby amended and restated, as follows: 

“Availability End Date” means October 24, 2017. 

“Term Loan Maturity Date” means October 24, 2020. 

 

	2)	Unless otherwise defined, all initially capitalized terms in this Amendment shall be as defined in the Agreement. The Agreement, as amended hereby, shall be and remain in full force and effect in accordance with its
respective terms and hereby is ratified and confirmed in all respects. Except as expressly set forth herein, the execution, delivery, and performance of this Amendment shall not operate as a waiver of, or as an amendment of, any right, power, or
remedy of Bank under the Agreement, as in effect prior to the date hereof. Borrower ratifies and reaffirms the continuing effectiveness of all agreements entered into in connection with the Agreement. 

 

	3)	Borrower represents and warrants that the representations and warranties contained in the Agreement are true and correct as of the date of this Amendment. 

 

	4)	This Amendment may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one instrument. 

 

	5)	As a condition to the effectiveness of this Amendment, Bank shall have received, in form and substance satisfactory to Bank, the following: 

a) this Amendment, duly executed by Borrower; 

b) payment of a $2,500 facility fee, which may be debited from any of Borrower’s accounts; 

c) payment of all Bank Expenses, including Bank’s expenses for the documentation of this Amendment and any related
documents, and any UCC, good standing 

 
or intellectual property search or filing fees, which may be debited from any of Borrower’s accounts; and 

d) such other documents and completion of such other matters, as Bank may reasonably deem necessary or appropriate. 

 
  
  

[Signature Page Follows] 

 IN WITNESS WHEREOF, the undersigned have executed this Amendment as of the first
date above written. 
  

									
	ALDEYRA THERAPEUTICS, INC.	 		 	PACIFIC WESTERN BANK
					
	By:	 	/s/ Stephen Tulipano	 		 	By:	 	/s/ Sean Noonan
	 Name:
 Title:
	 	 Stephen Tulipano
 CFO
	 		 	 Name:
 Title:
	 	 Sean Noonan
 VP

  
  

[Signature Page to Fifth Amendment to Loan and Security Agreement]EX-10.25

 Exhibit 10.25 

ALDEYRA THERAPEUTICS, INC. 

CHANGE IN CONTROL PLAN 

ARTICLE 1. INTRODUCTION. 

The Aldeyra Therapeutics, Inc. Change in Control Plan (the “Plan”) is established effective March 28, 2017 (the
“Effective Date”). The purpose of the Plan is to provide for the accelerated vesting for outstanding unvested equity awards held by eligible employees of Aldeyra Therapeutics, Inc. and its Affiliates (the “Company”)
if such employees are subject to a qualifying employment termination in connection with a Change in Control. This Plan shall supersede (i) any generally applicable severance or change in control plan, policy or practice, whether written or
unwritten, and (ii) any individually negotiated and signed employment contract or agreement solely with respect to the vesting of equity awards in connection with a Change in Control with respect to each employee who becomes a Participant in
the Plan. In addition, the Plan does not modify any post-employment covenants of a Participant pursuant to Company policies or agreements between the Participant and the Company. 

ARTICLE 2. DEFINITIONS. 

For purposes of the Plan, the following terms are defined as follows: 

(a) “Affiliate” means an entity that directly, or indirectly through one or more intermediaries, controls or
is controlled by, or is under common control with the Company. 
 (b) “Board” means the Board of Directors
of Aldeyra Therapeutics, Inc. 
 (c) “Cause” shall mean the Company’s good faith determination that any
one or more of the following has occurred with respect to the participant: 
 (i) an act or acts of personal dishonesty taken by the
Participant and intended to result in substantial personal enrichment of the Participant at the expense of the Company; 
 (ii) repeated
violations by the Participant of the Participant’s duties and obligations (other than as a result of incapacity due to physical or mental illness) which are demonstrably willful and deliberate on the Participant’s part, which are committed
in bad faith or without reasonable belief that such violations are in the best interests of the Company and which are not remedied in a reasonable period of time after receipt of written notice from the Company; 

(iii) indictment or plea of nolo contendere of Participant of a felony involving moral turpitude; or 

(iv) the material breach of the Participant’s Proprietary Information and Inventions Agreement. 

(d) “Change in Control” shall mean any of the following has occurred: 

  
 1 

 (i) Any “person” (as such term is used in Sections 13(d) and 14(d) of the Exchange
Act) becomes the “beneficial owner” (as defined in Rule 13d-3 of the Exchange Act), directly or indirectly, of securities of the Company representing more than fifty percent (50%) of the total voting power represented by the
Company’s then-outstanding voting securities; 
 (ii) The consummation of the sale or disposition by the Company of all or
substantially all of the Company’s assets; 
 (iii) The consummation of a merger or consolidation of the Company with or into any other
entity, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of
the surviving entity or its parent) more than fifty percent (50%) of the total voting power represented by the voting securities of the Company or such surviving entity or its parent outstanding immediately after such merger or consolidation;
or 
 (iv) Individuals who are members of the Board (the “Incumbent Board”) cease for any reason to constitute at least a
majority of the members of the Board over a period of 12 months; provided, however, that if the appointment or election (or nomination for election) of any new Board member was approved or recommended by a majority vote of the members of the
Incumbent Board then still in office, such new member shall, for purposes of this Plan, be considered as a member of the Incumbent Board. 

(v) A transaction shall not constitute a Change in Control if its sole purpose is to change the state of the Company’s incorporation or
to create a holding company that will be owned in substantially the same proportions by the persons who held the Company’s securities immediately before such transaction. In addition, if a Change in Control constitutes a payment
event with respect to any Award which provides for a deferral of compensation and is subject to Code Section 409A, then notwithstanding anything to the contrary in the Plan or applicable Award Agreement the transaction with respect to such
Award must also constitute a “change in control event” as defined in Treasury Regulation Section 1.409A-3(i)(5) to the extent required by Code Section 409A.

(e) “Change in Control Termination” means either an Involuntary Termination or a termination for Good Reason,
in each case, that occurs within three (3) months prior to or within twelve (12) months following the effective date of a Change in Control. 

(f) “Code” means the Internal Revenue Code of 1986, as amended. 

(g) “Company” means Aldeyra Therapeutics, Inc., its Affiliates, any successor to Aldeyra Therapeutics, Inc.
and, following a Change in Control, the surviving or controlling entity resulting from such a Change in Control or the entity to which the Company’s assets were transferred in the case where the Change in Control is an asset sale. 

(h) “Exchange Act” means the Securities Exchange Act of 1934, as amended. 

  
 2 

 (i) Good Reason” shall mean with respect to a Category I Participant:

 (i) a material diminution in a Participant’s base salary or target bonus by more than 10% (unless in connection with
a company wide cost reduction); 
 (ii) a material diminution in Participant’s authority, duties or responsibilities
with respect to the Company or any successor or acquiring entity, including, without limitation, any requirement that a Participant who is the Chief Executive Officer report to anyone other than to the Board of Directors of the ultimate parent
entity of the Company (the “Ultimate Parent Company”) or that a Participant (other than the Chief Executive Officer) report to anyone other than the Chief Executive Officer of the Ultimate Parent Company; 

(iii) a breach of a material provision of Participant’s employment or other written agreement governing employment with
the Company (it being understand that a change in title without Participant’s consent shall be a material breach); or 

(iv) without Participant’s prior consent, a relocation of his/her principal workplace by more than fifty (50) miles
away from the location which the Participant was working immediately prior to the required relocation. 
 A termination shall
not be a Good Reason unless (x) the Participant gives the Company written notice of such condition within 90 days after such condition first comes into existence, (y) the Company fails to remedy such condition within 30 days after
receiving the Participant’s written notice, and (z) the Participant has a Separation within 30 days of the expiration of the cure period described in clause (y) provided that the Company has not cured the Good Reason event or
condition. 
 (j) “Good Reason” shall mean with respect to a Category II Participant: 

(i) a material diminution in the Participant’s base compensation, except in connection with across-the-board salary reductions for all
similarly situated employees; or 
 (ii) without Participant’s prior consent, a relocation of his/her principal workplace by more than
fifty (50) miles away from the location which the Participant was working immediately prior to the required relocation. 
 A termination shall not be a
Good Reason unless (x) the Participant gives the Company written notice of such condition within 90 days after such condition first comes into existence, (y) the Company fails to remedy such condition within 30 days after receiving the
Participant’s written notice, and (z) the Participant has a Separation within 30 days of the expiration of the cure period described in clause (y) provided that the Company has not cured the Good Reason event or condition. 

(k) “Involuntary Termination” means a Participant’s involuntary termination of employment by the Company
resulting in a Separation for a reason other than 

  
 3 

 
Cause, provided that the Participant is willing and able to continue performing services within the meaning of Treasury Regulation Section 1.409A-1(n)(1). 

(l) “Participant” means an individual who is employed by the Company or its Affiliates. “Category I
Participant,” is an employee of the Company or Affiliate who has one of the following job titles: Chief Executive Officer, Chief Financial Officer or Chief Medical Officer or any other officers of the Company under Rule 16a-1(f) of the Securities Exchange Act of 1934 who report to Chief Executive Officer of the Company. “Category II Participant,” is all other employees of the Company other than Category I
Participants. 
 (m) “Plan Administrator” means the Company or any person or committee duly authorized by
the Company to administer the Plan. 
 (n) “Separation” means a “separation from service” with the
Company within the meaning of Treasury Regulation Section 1.409A-1(h), without regard to any permissible alternative definition thereunder. 

ARTICLE 3. ELIGIBILITY FOR BENEFITS. 

(a) General Rules. Subject to the provisions set forth in this Article 3 and Article 5, in the event of a Change in
Control Termination, the Company will provide the benefits described in Article 4 of the Plan to each affected Participant. 

(b) Exceptions to Benefit Entitlement. An employee, including an employee who otherwise is a Participant, will not
receive benefits under the Plan (or will receive reduced benefits under the Plan) in the following circumstances, as determined by the Plan Administrator in its sole and reasonable discretion: 

(i) The employee voluntarily terminates employment with the Company in order to accept employment with another entity that is controlled
(directly or indirectly) by the Company or is otherwise an Affiliate of the Company. 
 (ii) The employee terminates or is terminated for
any reason other than a Change in Control Termination. 
 (iii) The employee has failed to return all company property, including but not
limited to, keys (electronic and mechanical), laptop, projector, pager, software, training manuals, credit cards, access badges, and all hard copy and soft copy files and/or documents (including copies thereof). If any Company property is lost, the
employee may cure his or her failure to return such property by signing a declaration under oath that the property has been lost and reimbursing the Company for its replacement cost. As a condition to receiving benefits under the Plan, Participants
must not make or retain copies, reproductions or summaries of any such Company documents, materials or property. However, a Participant is not required to return his or her personal copies of documents evidencing the Participant’s hire,
termination, compensation, benefits and equity awards and any other documentation received as a stockholder of the Company. 

  
 4 

 (c) Termination of Benefits. A Participant’s right to receive the
payment of benefits under this Plan shall terminate immediately if, at any time prior to or during the period for which the Participant is receiving benefits hereunder, the Participant, without the prior written approval of the Plan Administrator:

 (i) willfully breaches a material provision of the Participant’s Proprietary Information and Inventions Agreement with the Company;

 (ii) willfully encourages or solicits any of the Company’s then current employees to leave the Company’s employ; 

(iii) willfully disparages, defames, libels or slanders the Company, its Affiliates, business concerns, past and present, and each of them, as
well as each of their partners, trustees, directors, officers, agents, attorneys, servants and employees, past and present, and each of them; or 

(iv) willfully violates any post-employment covenants contained in any other agreement between the Participant and the Company. 

ARTICLE 4. CHANGE IN CONTROL TERMINATION BENEFITS. 

(a) Outstanding Equity. If a Category I Participant or a Category II Participant experiences a Change in Control
Termination, then notwithstanding anything to the contrary in the Company’s 2013 Equity Incentive Plan, 2010 Employee, Director and Consultant Equity Incentive Plan and any other equity or stock option plan governing equity awards or stock
option agreements or other plan or agreements, then all outstanding unvested options and equity awards shall be fully vested and non-forfeitable. 

(b) Other Employee Benefits. If a Participant experiences a Change in Control Termination, all other benefits (such as
life insurance, disability coverage, and 401(k) plan coverage) shall terminate as of the date of such Change in Control Termination (except to the extent that a conversion privilege may be available thereunder). 

ARTICLE 5. LIMITATION ON BENEFITS. 

(a) Non-Duplication of Benefits. Except as otherwise specifically provided for herein, no Participant is eligible to
receive benefits under this Plan or pursuant to other contractual obligations more than one time. This Plan is designed to provide change in control benefits to Participants pursuant to the terms and conditions set forth in this Plan. The payments
pursuant to this Plan are in addition to, and not in lieu of, any unpaid salary, bonuses or benefits (other than change in control vesting benefits) to which a Participant may be entitled for the period ending with the Participant’s Change in
Control Termination. 
 (b) Parachute Payments. Except as otherwise provided in an agreement between a Participant and
the Company, if any payment or benefit the Participant would receive in connection with a Change in Control from the Company or otherwise (“Payment”) would (i) constitute a “parachute payment” within the meaning of
Section 280G of the Code, and (ii) but for this sentence, be subject to the excise tax imposed by Section 4999 of the Code 

  
 5 

 
(the “Excise Tax”), then such Payment shall be equal to the Reduced Amount. The “Reduced Amount” shall be either (x) the largest portion of the Payment that would
result in no portion of the Payment being subject to the Excise Tax, or (y) the largest portion, up to and including the total, of the Payment, whichever amount, after taking into account all applicable federal, state and local employment
taxes, income taxes, and the Excise Tax (all computed at the highest applicable marginal rate), results in the Participant’s receipt of the greatest economic benefit notwithstanding that all or some portion of the Payment may be subject to the
Excise Tax. If a reduction in payments or benefits constituting “parachute payments” is necessary so that the Payment equals the Reduced Amount, any reduction shall be applied first, on a pro rata basis, to amounts that constitute
deferred compensation within the meaning of Section 409A of the Code, and, in the event that the reductions pursuant to this Article 5(b) exceed payments that are subject to Section 409A of the Code, the remaining reductions shall be
applied, on a pro rata basis, to any other remaining payments. The Company’s determinations hereunder shall be final, binding and conclusive on all interested parties. 

ARTICLE 6. RIGHT TO INTERPRET PLAN; AMENDMENT AND TERMINATION. 

(a) Exclusive Discretion. The Plan Administrator shall have the discretion and authority to establish rules, forms, and
procedures for the administration of the Plan and to construe and interpret the Plan and to decide any and all questions of fact, interpretation, definition, computation or administration arising in connection with the operation of the Plan,
including, but not limited to, the eligibility to participate in the Plan and amount of benefits paid under the Plan. The rules, interpretations, computations and other actions of the Plan Administrator shall be binding and conclusive on all
persons. 
 (b) Amendment. The Company reserves the right to amend this Plan (including but not limited to changing
the designation of any Participant as a Category I Participant or Category II Participant, and the benefits provided hereunder at any time; provided, however, that (i) no such amendment shall reduce or otherwise adversely affect the
benefits provided in Article 4 to a Participant unless such Participant consents in writing to such amendment, and (ii) no such amendment shall occur following the date of entry into a definitive agreement that would result in a Change in
Control as to any Participant who would be adversely affected by such amendment unless such Participant consents in writing to such amendment. 

(c) Initial Term, Automatic Renewal and Termination. The Plan shall have an initial three-year term that expires on
December 31, 2019. The Plan shall automatically renew for a series of additional one-year terms, unless the Plan Administrator provides written notification to Participants, at least six months prior to the intended Plan termination date, of
the Company’s intent to terminate the Plan effective as of the end of the current term. Notwithstanding the foregoing, upon the occurrence of a Change in Control, the Plan shall be extended to terminate upon the later of (i) the end of the
current term, or (ii) the second anniversary of the effective date of such Change in Control. 

  
 6 

 ARTICLE 7. NO IMPLIED EMPLOYMENT CONTRACT. 

The Plan shall not be deemed (a) to give any employee or other person any right to be retained in the employ of the Company, or
(b) to interfere with the right of the Company to discharge any employee or other person at any time, with or without cause, and with or without advance notice, which right is hereby reserved. 

ARTICLE 8. LEGAL CONSTRUCTION. 

This Plan shall be governed by and shall be construed in accordance with the laws of the Commonwealth of Massachusetts (without regard to
principles of conflict of laws). 
 ARTICLE 9. GENERAL PROVISIONS. 

(a) Notices. Any notice, demand or request required or permitted to be given by either the Company or a Participant
pursuant to the terms of this Plan shall be in writing and shall be deemed given when delivered personally or deposited in the U.S. mail, First Class with postage prepaid, and addressed to the parties, in the case of a Participant, at the address as
set forth in the Company’s employment file maintained for the Participant as previously furnished by the Participant or such other address as a party may request by notifying the other in writing. 

(b) Employment at Will. Employment with the Company is for no specific period of time. Participation in the Plan does
not confer any right to continued employment, and a Participant’s employment with the Company is “at will.” 

(c) Transfer and Assignment. The rights and obligations of a Participant under this Plan may not be transferred or
assigned without the prior written consent of the Company. This Plan shall be binding upon any surviving entity resulting from a Change in Control and upon any other person who is a successor by merger, acquisition, consolidation or otherwise to the
business formerly carried on by the Company without regard to whether or not such person or entity actively assumes the obligations hereunder. 

(d) Waiver and Costs of Enforcement. Any party’s failure to enforce any provision or provisions of this Plan shall
not in any way be construed as a waiver of any such provision or provisions, nor prevent any party from thereafter enforcing each and every other provision of this Plan. The rights granted to the parties herein are cumulative and shall not
constitute a waiver of any party’s right to assert all other legal remedies available to it under the circumstances. All out-of-pocket costs and expenses reasonably incurred by a Participant (including attorneys’ fees) in connection with
enforcing the Participant’s rights under the Plan shall be paid by the Company if such rights relate to a Change in Control Termination that occurs any time after the effective date of the first Change in Control that occurs after the
Participant commences participation in the Plan. Notwithstanding the foregoing, if the Participant initiates any claim or action and the claim or action is either totally without merit or frivolous, the Participant shall be responsible for the
Participant’s own costs and expenses. 

  
 7 

 (e) Jurisdiction. The parties hereto intend to and hereby confer
jurisdiction to enforce the Plan upon the state and federal courts sitting in the Commonwealth of Massachusetts. 
 (f)
Severability. Should any provision of this Plan be declared or determined to be invalid, illegal or unenforceable, the validity, legality and enforceability of the remaining provisions shall not in any way be affected or impaired. 

(g) Survival. The rights and obligations of the parties under the provisions of this Plan shall survive, and remaining
binding and enforceable, notwithstanding the termination of Participant’s employment hereunder or otherwise, to the extent necessary to preserve the intended benefits of such provision. 

(h) Article Headings. Article headings in this Plan are included for convenience of reference only and shall not be
considered part of this Plan for any other purpose. 
 ARTICLE 10. EXECUTION 

To record the adoption of the Plan as set forth herein, Aldeyra Therapeutics, Inc. has caused its duly authorized officer to execute the same
as of the Effective Date. 
  

			
	ALDEYRA THERAPEUTICS, INC.
		
	By:	 	/s/ Todd C. Brady
	 Name:
 Title:
	 	 Todd C. Brady
 President and Chief Executive
Officer

  
 8

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00269-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00269-of-00352.parquet"}]]